Novo’s Ozempic, Wegovy Targeted in Medicare Price Negotiations

Centers for Medicare and Medicaid Services announced selection of 15 additional drugs covered under Medicare Part D for price negotiation including Novo’s Ozempic & Wegovy.

• More drugs that will be subject to the negotiating for Medicare include
• Trelegy Ellipta
• Xtandi
• Pomalyst
• Ibrance
• Ofev
• Linzess
• Calquence
• Austedo; Austedo XR
• Breo Ellipta
• Tradjenta
• Xifaxan
• Vraylar
• Janumet; Janumet XR
• Otezla

CMS: HHS Announces 15 Additional Drugs Selected for Medicare Drug Price Negotiations in Continued Effort to Lower Prescription

To contact the reporter on this story:
Chakradhar Adusumilli in New York at cadusumilli@bloomberg.net

To contact the editor responsible for this story:
Zachary Fleming ...